There’s a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on KKR & Co (KKR – Research Report), Ladder Capital (LADR – Research Report) and GooseHead Insurance (GSHD – Research Report) with bullish sentiments.
KKR & Co (KKR)
JMP Securities analyst Brian McKenna reiterated a Buy rating on KKR & Co yesterday and set a price target of $85.00. The company’s shares closed last Thursday at $46.39, close to its 52-week low of $44.28.
According to TipRanks.com, McKenna is a 1-star analyst with an average return of
KKR & Co has an analyst consensus of Strong Buy, with a price target consensus of $78.35.
See Insiders’ Hot Stocks on TipRanks >>
Ladder Capital (LADR)
JMP Securities analyst Steven Delaney reiterated a Buy rating on Ladder Capital today and set a price target of $13.50. The company’s shares closed last Thursday at $10.81.
According to TipRanks.com, Delaney is a 5-star analyst with an average return of
Ladder Capital has an analyst consensus of Moderate Buy, with a price target consensus of $13.50.
GooseHead Insurance (GSHD)
JMP Securities analyst Matthew Carletti reiterated a Buy rating on GooseHead Insurance today and set a price target of $120.00. The company’s shares closed last Thursday at $46.16, close to its 52-week low of $39.00.
According to TipRanks.com, Carletti is a 2-star analyst with an average return of
Currently, the analyst consensus on GooseHead Insurance is a Moderate Buy with an average price target of $97.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KKR:
- Rosenblatt Securities Thinks Splunk’s Stock is Going to Recover
- BTIG Sticks to Their Buy Rating for The Chefs’ Warehouse (CHEF)
- BTIG Maintains a Hold Rating on Darden (DRI)
- Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and LumiraDx (LMDX)
- Taysha Gene Therapies (TSHA) Gets a Buy Rating from Robert W. Baird